The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
ETCTN 10366: A phase 1 study of DNA-PK inhibitor peposertib in combination with hypofractionated radiotherapy for the treatment of locally advanced pancreatic adenocarcinoma.
 
S. Lindsey Davis
Stock and Other Ownership Interests - Johnson & Johnson/MedTech
Speakers' Bureau - Allergan (I)
Research Funding - Boston Scientific (I); Bristol-Myers Squibb (Inst); EMD Serono (Inst); I-Mab (Inst); Merck (Inst); ORIC Pharmaceuticals (Inst); Symphogen (Inst); TriSalus Life Sciences (Inst); Tvardi Therapeutics (Inst)
 
Anup Kasi
Consulting or Advisory Role - Cardinal Health; Ipsen
Research Funding - Ability Pharma (Inst); Astellas Pharma (Inst); Bavarian Nordic (Inst); Cardiff Oncology (Inst); Cend Therapeutics (Inst); FibroGen (Inst); Geistlich Pharma (Inst); Novocure (Inst); Rafael Pharmaceuticals (Inst); TESARO (Inst)
 
Farshid Dayyani
Employment - Roche (I)
Consulting or Advisory Role - AstraZeneca; Eisai; Exelixis
Speakers' Bureau - Astellas Pharma; Exelixis; ipsen; SERVIER; Sirtex Medical
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); Genentech (Inst); Ipsen (Inst); Merck (Inst); Taiho Pharmaceutical (Inst)
 
Allyson J. Ocean
Leadership - Novocure
Stock and Other Ownership Interests - Novocure
Consulting or Advisory Role - Guardant Health; Natera
Speakers' Bureau - Guardant Health; Natera
Travel, Accommodations, Expenses - Guardant Health; Natera; Novocure
 
Vincent Chung
Consulting or Advisory Role - Perthera
Speakers' Bureau - AstraZeneca; Coherus Biosciences; Ipsen
Research Funding - Merck (Inst)
 
Mohammed Najeeb Al Hallak
Speakers' Bureau - AstraZeneca; Guardant Health; Ipsen; Seagen; Takeda
 
Christos Fountzilas
Research Funding - Amgen (Inst); Aravive (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bellicum Pharmaceuticals (Inst); Biomea Fusion (Inst); Bristol-Myers Squibb/Ono Pharmaceutical (Inst); Corcept Therapeutics (Inst); CrystalGenomics (Inst); Dragonfly Therapeutics (Inst); ERYTECH Pharma (Inst); Ipsen (Inst); Kadmon (Inst); Legend Biotech USA Inc (Inst); Lilly (Inst); Merck (Inst); Pfizer (Inst); Rafael Pharmaceuticals (Inst); Sanofi (Inst); Seagen (Inst); Taiho Oncology (Inst); TransThera Biosciences (Inst); Valar Labs (Inst)
Travel, Accommodations, Expenses - CG Pharmaceuticals
 
Junxiao Hu
No Relationships to Disclose
 
Judy Murray
No Relationships to Disclose
 
Carmen Allegra
Consulting or Advisory Role - Novartis
 
Steven Gore
No Relationships to Disclose
 
Jan Hendrik Beumer
Employment - Voisin Consulting (I)
Stock and Other Ownership Interests - GlaxoSmithKline (I)
Research Funding - TriSalus Life Sciences (Inst)
Patents, Royalties, Other Intellectual Property - Sulphoraphane for melanoma chemoprevention (Inst)
Expert Testimony - Astellas Pharma; AstraZeneca/Merck
(OPTIONAL) Uncompensated Relationships - Applied Isotope Technologies; Qrono
 
Karyn A. Goodman
Consulting or Advisory Role - Novartis; Philips Healthcare; RenovoRx; Roche/Genentech
Other Relationship - National Cancer Institute